MELISSA AIDA SILVA

Allopathic & Osteopathic Physicians|Family Medicine SUGAR LAND, TX NPI 1013404896

General Payments — all program years on this page

$633.78

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 28
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $381.93 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $381.9320

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2022 $39.202
2023 $212.656
2024 $381.9320

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1089513382 Currax Pharmaceuticals LLC $17.37 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097585874 Novo Nordisk Inc $18.62 03/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104233249 AstraZeneca Pharmaceuticals LP $18.35 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104334338 AstraZeneca Pharmaceuticals LP $15.66 07/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104448377 AstraZeneca Pharmaceuticals LP $15.45 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104671147 AstraZeneca Pharmaceuticals LP $15.39 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105369756 AstraZeneca Pharmaceuticals LP $16.19 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105664976 AstraZeneca Pharmaceuticals LP $18.78 04/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105796956 AstraZeneca Pharmaceuticals LP $47.68 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105900358 AstraZeneca Pharmaceuticals LP $14.62 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106102615 ABBVIE INC. $19.13 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116125824 GlaxoSmithKline, LLC. $13.74 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116364279 GlaxoSmithKline, LLC. $18.07 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116489518 GlaxoSmithKline, LLC. $19.87 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117383224 Amgen Inc. $16.65 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117836880 Boehringer Ingelheim Pharmaceuticals, Inc. $20.31 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135188445 Lilly USA, LLC $14.95 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135201099 Lilly USA, LLC $19.39 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153321610 Dexcom, Inc. $23.74 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153321612 Dexcom, Inc. $17.97 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.